Plus: New capital for CytoReason, Truvian and Renalys

Gene therapy vectors that deliver biologic drugs enter late-state clinical trials

Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss

Project ALS and Medical Excellence-backed company hopes to take same regulatory path forged by Amylyx

Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders

More than half of clinical AAV programs target neurology and ophthalmic conditions

NGM appears set to move on from NASH after aldafermin missed the primary endpoint in the Phase IIb ALPINE 2/3 trial, but further analyses from the trial will be needed to help explain whether a